1. Introduction {#sec1-marinedrugs-14-00077}
===============

The most primitive benthic marine organisms are also among the most chemodiversified producers of secondary metabolites (SM). These compounds are used for predation and competition for space, as well as for communication, and protection against potential surrounding aggressors. Due to the high water dilution, the produced metabolites exhibit several potent biological activities \[[@B1-marinedrugs-14-00077]\]. Several reviews dealing with bioactive marine natural products, in particular, alkaloids have been published in the last few decades \[[@B2-marinedrugs-14-00077],[@B3-marinedrugs-14-00077],[@B4-marinedrugs-14-00077],[@B5-marinedrugs-14-00077],[@B6-marinedrugs-14-00077],[@B7-marinedrugs-14-00077],[@B8-marinedrugs-14-00077],[@B9-marinedrugs-14-00077],[@B10-marinedrugs-14-00077],[@B11-marinedrugs-14-00077],[@B12-marinedrugs-14-00077],[@B13-marinedrugs-14-00077],[@B14-marinedrugs-14-00077],[@B15-marinedrugs-14-00077],[@B16-marinedrugs-14-00077],[@B17-marinedrugs-14-00077],[@B18-marinedrugs-14-00077],[@B19-marinedrugs-14-00077]\]. Of the many different marine species that have been researched, sponges are likely to be the most studied sources of marine natural products due to the large amount of structurally diverse SM scaffolds they produce. Even so, the last few years have seen a slight decline in the number of newly described metabolites \[[@B17-marinedrugs-14-00077],[@B18-marinedrugs-14-00077]\].

In this review, we focused on the chemodiversity and biological activities of batzelladine- and crambescidin-like guanidine alkaloids isolated from Poecilosclerida marine sponges. These polycyclic guanidine alkaloids are extremely versatile SM \[[@B20-marinedrugs-14-00077]\]. Since their original isolation in 1989, several revisions have been made and many aspects remain to be studied. However, what is clear is that they seem to be specific to Poecilosclerida marine sponges. Over 53 derivatives have been isolated and their original structures, based on chemical degradation studies and extensive NMR and MS studies, have been revised since the development of their total synthesis. The structural and stereochemical complexity of this class of natural products have inspired the development of a number of new synthetic methodologies \[[@B21-marinedrugs-14-00077],[@B22-marinedrugs-14-00077],[@B23-marinedrugs-14-00077],[@B24-marinedrugs-14-00077],[@B25-marinedrugs-14-00077],[@B26-marinedrugs-14-00077],[@B27-marinedrugs-14-00077],[@B28-marinedrugs-14-00077],[@B29-marinedrugs-14-00077],[@B30-marinedrugs-14-00077],[@B31-marinedrugs-14-00077],[@B32-marinedrugs-14-00077],[@B33-marinedrugs-14-00077],[@B34-marinedrugs-14-00077]\], which in turn has led to several total syntheses \[[@B31-marinedrugs-14-00077],[@B33-marinedrugs-14-00077],[@B35-marinedrugs-14-00077],[@B36-marinedrugs-14-00077],[@B37-marinedrugs-14-00077],[@B38-marinedrugs-14-00077],[@B39-marinedrugs-14-00077],[@B40-marinedrugs-14-00077],[@B41-marinedrugs-14-00077],[@B42-marinedrugs-14-00077],[@B43-marinedrugs-14-00077],[@B44-marinedrugs-14-00077],[@B45-marinedrugs-14-00077],[@B46-marinedrugs-14-00077],[@B47-marinedrugs-14-00077],[@B48-marinedrugs-14-00077],[@B49-marinedrugs-14-00077],[@B50-marinedrugs-14-00077]\] beyond the scope of this review. Finally, these unique and fascinating structures are coupled with a wide range of biological activities due to the typical shape of their tricyclic skeleton. However, little is known about their exact mechanism of action.

2. Structural Diversity {#sec2-marinedrugs-14-00077}
=======================

From 1989 to 2015, 53 TGA (triazaacenaphthylene guanidine alkaloids) have been isolated. Natural TGA reported to date are listed in [Table 1](#marinedrugs-14-00077-t001){ref-type="table"} and [Table 2](#marinedrugs-14-00077-t002){ref-type="table"}.

Ptilomycalin A (**1**), isolated from the sponges *Ptilocaulis spiculifer* and *Hemimycale* sp. \[[@B51-marinedrugs-14-00077]\], is the parent member of a group of related metabolites. This includes crambescidins \[[@B52-marinedrugs-14-00077],[@B53-marinedrugs-14-00077],[@B54-marinedrugs-14-00077],[@B55-marinedrugs-14-00077]\] and their derivatives (isocrambescidine (**6**) \[[@B52-marinedrugs-14-00077],[@B56-marinedrugs-14-00077]\], crambidine (**7**) \[[@B52-marinedrugs-14-00077]\], neofolitispates (**8**--**10**) \[[@B57-marinedrugs-14-00077]\], crambescidin acid (**14**) \[[@B58-marinedrugs-14-00077]\], crambescidic acid (**15**) \[[@B59-marinedrugs-14-00077]\], ptilomycalin D (**17**) \[[@B60-marinedrugs-14-00077]\], monanchocidins (**18**--**22**) \[[@B61-marinedrugs-14-00077],[@B62-marinedrugs-14-00077]\], and monanchomycalins (**23**--**25**) \[[@B63-marinedrugs-14-00077],[@B64-marinedrugs-14-00077]\]), which are found in several sponges (*Crambe crambe*, *Neofolitispa dianchora, Monanchora arbuscula*, *Monanchora ungiculata,* *Monanchora dianchora*, and *Monanchora pulchra*), as well as, for a subset, in the New Caledonian starfishes *Fromia monilis* and *Celerina heffernani* ([Table 1](#marinedrugs-14-00077-t001){ref-type="table"}) \[[@B65-marinedrugs-14-00077]\]. Additional guanidine derivatives have been isolated, such as the batzelladines A--E (**26**--**30**) from the Bahamanian sponge *Batzella* sp. (which has since been revised to *Crambe crambe*) \[[@B66-marinedrugs-14-00077]\], batzelladines F--I (**31**--**34**) from the Jamaican sponge *Batzella* sp. \[[@B67-marinedrugs-14-00077]\], batzelladine J (**51**) from the Caribbean sponge *Monanchora unguifera* \[[@B59-marinedrugs-14-00077]\], and their derivatives (clathriadic acid (**41**) \[[@B68-marinedrugs-14-00077]\], merobatzelladines (**42**,**43**) \[[@B69-marinedrugs-14-00077]\], and batzellamide A (**50**) \[[@B70-marinedrugs-14-00077]\]) from *Monanchora unguifera*, *Clathria calla*, and *Monanchora arbuscula* ([Table 2](#marinedrugs-14-00077-t002){ref-type="table"}).

TGA are only found in Poecilosclerida marine sponges. To date, they have been only isolated from the Crambidae *(Crambe*, *Monanchora*), Mycalidae *(Arenochalina*, *Mycale*), Phoriospongidae *(Batzella*, *Hemimycale*), and Microcionidae (C*lathria*) families \[[@B71-marinedrugs-14-00077]\]. Sponges that produce TGA can be found in warm waters, without distinction between oceans and seas. A large majority were sampled in the Caribbean Sea ([Figure 1](#marinedrugs-14-00077-f001){ref-type="fig"}).

Since 1989, the number of new TGA discovered each year is considered as almost constant, although it should be noted that in some years no new TGA were described ([Figure 2](#marinedrugs-14-00077-f002){ref-type="fig"}).

2.1. TGA Structures {#sec2dot1-marinedrugs-14-00077}
-------------------

Each TGA is structurally closely related to the others. Crambescidins-like GA differ from one another, by the C-8 spiro ring, the presence or absence of a hydroxyl group at C-13 or the nature of the side chain terminus at C-14.

The structures of 22 related crambescidin-like GA are summarized in [Figure 3](#marinedrugs-14-00077-f003){ref-type="fig"}.

Other derivatives such as 13,14,15-isocrambescidin 800 (**6**), crambidin (**7**) or 16β-hydroxycrambescidin 359 (**16**) have also been isolated ([Figure 4](#marinedrugs-14-00077-f004){ref-type="fig"}).

Compared to crambescidin-like GA, batzelladines-like GA present more structural variations. Structurally, all of the batzelladines share a decahydro- or octahydro-5,6,8b-triazaacenaphthalene core with different degrees of oxidation. Batzelladines A--I (**26**--**34**) all possess at least one tricyclic guanidine core that contains either a *syn* or *anti* stereo relationship of the angular hydrogens that flank the pyrrolidine nitrogen \[[@B76-marinedrugs-14-00077]\]. To this, tricyclic guanidine core are connected, through an ester linkage, and additional guanidine fragments of varying complexity. Batzelladines F (**31**), G (**32**), and L (**38**) all possess an additional tricyclic hydroxy-guanidine fragment, while the simplest members of the family, batzelladines C (**28**), D (**29**), and E (**30**), possess a common 4-guanidino-butyl unit. The more complex batzelladines, A (**26**) and B (**27**), are attached to an analogue of crambescin A (**54**) ([Figure 5](#marinedrugs-14-00077-f005){ref-type="fig"}). Batzelladines F (**31**) and J (**36**) are composed of two 5,6,6a-triaza-acenaphthalene cores linked via an aliphatic chain.

The structures of several members of the batzelladines have been revised since their original isolation. The originally proposed structures were based on chemical degradation studies, NMR spectroscopy analysis (1D and 2D), and comparison of the data to previously reported polycyclic guanidine such as ptilomycalin A (**1**). Since the original isolation work, the structures of batzelladines A (**26**), D (**29**), E (**30**), and F (**31**) have all been revised to their current structures after their partial or total synthesis \[[@B27-marinedrugs-14-00077],[@B28-marinedrugs-14-00077],[@B29-marinedrugs-14-00077],[@B30-marinedrugs-14-00077],[@B35-marinedrugs-14-00077],[@B39-marinedrugs-14-00077]\]. As a consequence of these reassignments, the relative stereochemistry of batzelladines G (**32**), H (**33**), and I (**34**) has been reexamined \[[@B30-marinedrugs-14-00077]\].

The current structures of 22 related batzelladine-like GA are summarized in [Figure 6](#marinedrugs-14-00077-f006){ref-type="fig"}.

Other batzelladine-like GA have been isolated such as batzelladine C (**28**), K (**37**), and E (**30**); dehydrobatzelladine C (**35**); clathriadic acid (**41**); and batzellamide A (**50**) ([Figure 7](#marinedrugs-14-00077-f007){ref-type="fig"}).

In summary, the structurally unique tricyclic guanidinium ring system (hydro-5,6,6atriazaacenapthalene) that defines this class of natural products can be found in over 53 different alkaloids. While each of these natural products share this common structural motif, the substituents around the tricyclic core of these molecules leads to a significant structural diversity, which relate to a wide-range of biological properties. For instance, a large number of these molecules including batzelladine F (**31**) and ptilomycalin A (**1**) feature esters that tether the tricyclic core to a diverse array of different functional groups, including other tricyclic guanidine subunits. The other area of structural diversity within this family of alkaloids is both the C1 and the C8 alkyl chains, which vary in terms of length, units of unsaturation, and oxidation. Remote oxidation of the alkyl branches is characteristic of the crambescidin alkaloids, including ptilomycalin A (**1**) and crambescidin 359 (**11**), which feature two spirocyclic hemiaminals as well as the tricyclic guanidine framework. In addition to structural diversity, batzelladines-like GA and crambescidins-like GA alkaloids feature different stereochemical configurations of the tricyclic core. Both the *trans*- and *cis*-configurations of the pyrrolidine subunit have been reported in this class of natural products. Batzelladine F (**31**) highlights this stereochemical diversity as it contains two distinct tricyclic guanidine subunits, with each featuring one of the pyrrolidine configurations. The stereochemical diversity is generally limited to the configuration of the pyrrolidine unit, as all of the alkaloids in this class feature a *trans* relationship between the C4 (and/or C6) proton and the C1 (and/or C8) alkyl chain, with the exception of merobatzelladines A (**42**) and B (**43**). Both natural products feature a *cis* relationship between the C6 proton and the C8 alkyl chain.

2.2. TGA Classification {#sec2dot2-marinedrugs-14-00077}
-----------------------

Different guanidine alkaloids classifications can be made, and, as such, Santos *et al.* (2015) have described four GA chemotypes \[[@B70-marinedrugs-14-00077]\]. The first class is constituted of a monocyclic pyrimidinamine skeleton, for example, crambescin C1 (**55**) or the bicyclic cyclopentapyrimidinamine skeleton, such as crambine A (**56**) ([Figure 8](#marinedrugs-14-00077-f008){ref-type="fig"}). The second one is a tricyclic triazaacenaphthylene skeleton, which only contains one guanidine moiety like crambescidins, and the third one possess the same skeleton as for class 2, but contains, at least, one more guanidine moiety, as can be seen in the case of most batzelladines. The fourth one is a tricyclic cyclopentaquinazolinamine skeleton like netamine M (**57**) or ptilocaulin (**58**).

Another classification can be made with the same first, second and fourth classes, and a modified third class describing pentacyclic triazaacenaphthylene skeletons like crambescidins (**1**--**25**) ([Table 3](#marinedrugs-14-00077-t003){ref-type="table"}).

Without taking into account any genus revision made, some observations may be outlined. According to the data reported, *Monanchora* is the most studied genus ([Table 1](#marinedrugs-14-00077-t001){ref-type="table"} and [Table 2](#marinedrugs-14-00077-t002){ref-type="table"}). Some species seem to produce both the crambescidins and batzelladines classes as is illustrated with *Monanchora unguifera*, which produces 16β-hydroxycrambescidin (**16**), crambescidic acid (**15**) and batzelladines J--L (**36**--**38**) ([Table 1](#marinedrugs-14-00077-t001){ref-type="table"} and [Table 2](#marinedrugs-14-00077-t002){ref-type="table"}). Other genera seem to produce only one TGA family. For example, to date, *Batzella* sp. was only shown to produce batzelladines A--I (**26**--**34**).

Interestingly, a chemotaxonomic study suggested that the biogenetically related guanidine alkaloids isolated from *Crambe crambe*, *Monanchora arbuscula*, *Ptilocaulis spiculifer*, and *Hemimycale* sp., should eventually be united in a single genus, preferentially *Crambe* \[[@B53-marinedrugs-14-00077]\].

2.3. Analytical Tools for TGA Structural Analysis {#sec2dot3-marinedrugs-14-00077}
-------------------------------------------------

TGA structural determinations have been accomplished based on extensive NMR (1D and 2D) and MS analyses, and chemical degradation.

The following section is a guideline for the structure determination of crambescidin- or batzelladine-like GA derivatives by their characteristic fragments via the use of NMR and MS analyses.

### 2.3.1. NMR Spectroscopy {#sec2dot3dot1-marinedrugs-14-00077}

TGA NMR spectra have a high content of information. Due to the relative signal richness, the ^1^H--^1^H COSY experiment is appropriate in helping to find whether one or another TGA class is present by analyzing the NMR spectra between 0.8 and 5 ppm. Nonetheless, several characteristic signals from different atoms listed below ([Figure 9](#marinedrugs-14-00077-f009){ref-type="fig"}) should be found in the ^1^H NMR spectra ([Table 4](#marinedrugs-14-00077-t004){ref-type="table"}).

#### Crambescidin Case: Ptilomycalin A (**1**)

As an example, we choose ptilomycalin A (**1**), which is part of the pentacyclic TGA class.

First of all, the H~1~ signal (triplet) and the H~4~ and H~5~ signals of the double bond are very characteristic. There are also clear correlations from H~1~ to H~5~, and finally, the NMR chemical shifts of H~a~, H~b,~ H~c,~ and H~d~ are also very characteristic within the crambescidin family ([Figure 10](#marinedrugs-14-00077-f010){ref-type="fig"}) ([Table 4](#marinedrugs-14-00077-t004){ref-type="table"}).

#### Batzelladine Case: Batzelladine F (**31**)

In general, all the NMR signals reported in [Table 4](#marinedrugs-14-00077-t004){ref-type="table"} are more shielded in batzelladines than in crambescidins. Moreover, the NMR spectra are more complex and are often different since the guanidinium core can be once or more dehydrogenated.

Within the tricyclic TGA class 2, we used the example of batzelladine F (**31**).

The major difference between batzelladine F and ptilomycalin A spectra is the absence of the signals for the protons H~4~ and H~5~, and the corresponding correlation. On the other hand, two correlations are very characteristic within batzelladines: H~a~ with H~b~, and H~c~ with H~d~ ([Figure 11](#marinedrugs-14-00077-f011){ref-type="fig"}).

### 2.3.2. Mass Spectrometry {#sec2dot3dot2-marinedrugs-14-00077}

Several TGA were detected by positive electrospray mass spectrometry ionization studies. Usually, authors notify the TGA quasi-molecular ion \[M + H\]^+^ with the exception of batzelladines M (**39**) and N (**40**), which were detected through their dicharged ion \[M + 2H\]^2+^ \[[@B73-marinedrugs-14-00077]\]. On the other hand, both quasi-molecular and discharged ions were observed for batzelladine L (**38**) and monanchomycalin C (**25**). Mass spectrometry data for TGA are summarized in [Table 5](#marinedrugs-14-00077-t005){ref-type="table"}.

Tandem mass spectrometry (MS²) experiments were also performed to confirm a hypothesis or provide additional information concerning the TGA side chains, as reported in [Table 6](#marinedrugs-14-00077-t006){ref-type="table"}.

3. Biological Activities {#sec3-marinedrugs-14-00077}
========================

TGA exhibited a wide range of biological activities with mainly antiviral, antimicrobial (including antifungal, antibacterial, anti-yeast, and antiparasitic), and antitumor properties.

3.1. Antiviral Activities {#sec3dot1-marinedrugs-14-00077}
-------------------------

Several TGA derivatives were evaluated for their antiviral activities against different viruses such as Human immunodeficiency virus (HIV-1), *Herpes simplex* virus (HSV-1), and Human hepatitis B virus (HBV). The reported data for 17 TGA are summarized in [Table 7](#marinedrugs-14-00077-t007){ref-type="table"}.

In general, crambescidin-like GA seem to be more efficient against HIV compared to batzelladine-like GA (half maximal effective concentration (EC~50~) around 1 mM \[[@B66-marinedrugs-14-00077],[@B73-marinedrugs-14-00077]\]) with EC~50~ activities below 0.05 µM \[[@B51-marinedrugs-14-00077],[@B73-marinedrugs-14-00077]\]. The stereochemistry of the molecule has a great influence on the antiviral activity. For example, 13,14,15-isocrambescidin (**6**) is not active against HSV-1 compared to crambescidins \[[@B56-marinedrugs-14-00077]\]. Ptilomycalin A (**1**) shows very potent anti-HIV-1 and anti-HSV-1 activities at a concentration of 0.011 and 0.25 µM, respectively \[[@B51-marinedrugs-14-00077]\], which makes it the best antiviral candidate.

Surprisingly, neofolitispates (**8**--**10**) are the only crambescidin-like GA derivatives that have been tested on HBV and exhibited an anti-HBV activity \[[@B57-marinedrugs-14-00077]\]. Unfortunately, few details have been reported.

On the other hand, batzelladines A--E (**26**--**30**) were shown to block the interaction between the surface of the HIV envelope glycoprotein gp120 and the extracellular domains of human CD4 receptor protein \[[@B77-marinedrugs-14-00077]\]. This binding is vital to the replication of the virus as it controls its entry into the human cells, since without access to the biochemical environment within the cell the virus is unable to replicate. As a consequence, batzelladines have a therapeutic interest in the treatment of HIV \[[@B76-marinedrugs-14-00077]\].

To date, batzelladine-like GA have not been tested against HSV or HBV viruses.

3.2. Antimicrobial Activities {#sec3dot2-marinedrugs-14-00077}
-----------------------------

TGA derivatives were tested against several bacteria (*Mycobacterium tuberculosis*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Mycobacterium intracellulare*), yeast (*Candida albicans*), fungi (*Cryptococcus neoformans* and *Aspergillus fumigatus*), and parasites (*Plasmodium falciparum*, *Tripanosoma cruzi*, *Leishmania infatum*, and *Trypanosoma brucei brucei*). [Table 8](#marinedrugs-14-00077-t008){ref-type="table"} reports all the antimicrobial activity results for 19 TGA tested.

Crambescidin 800 (**2**) and ptilomycalin A (**1**) exhibited potent activity against most bacteria, yeast, fungi, and parasites \[[@B68-marinedrugs-14-00077],[@B73-marinedrugs-14-00077]\]. Curiously, they are poorly active on *Mycobacterium intracellulare* and are considered inactive on *Mycobacterium tuberculosis* (*M. tuberculosis*) \[[@B73-marinedrugs-14-00077]\]. Furthermore, 16β-hydroxycrambescidin (**16**), the only crambescidin-like GA bearing a hydroxyl group on its pentacycle, was not active against all the strains tested \[[@B73-marinedrugs-14-00077]\].

In some cases, Batzelladine-like GA present similar activities compared to crambescidin-like GA. Batzelladines C (**28**) and L (**38**) are often the more potent molecules \[[@B73-marinedrugs-14-00077]\]. Nevertheless, batzelladine M (**39**) is the less active TGA class 2 and surprisingly, the same authors showed batzelladine N (**40**) to be nine times more efficient compared to batzelladine M (**39**) against *M. tuberculosis* (minimum inhibitory concentration (MIC) 3.18 and 28.5 µg·mL^−1^, respectively), despite their chemical structures being closely related \[[@B73-marinedrugs-14-00077]\].

3.3. Antitumoral Activities {#sec3dot3-marinedrugs-14-00077}
---------------------------

Over 20 TGA were tested for their cytotoxicity against several cancer cell lines such as prostate, ovary, breast, melanoma leukemia, pancreas, colon, and cervix ([Table 9](#marinedrugs-14-00077-t009){ref-type="table"}).

Ptilomycalin A (**1**) is once again the most active TGA tested as its half maximal growth inhibition values (GI~50~) are always below 0.1 µg/mL on all the cell lines tested \[[@B73-marinedrugs-14-00077]\]. Crambescidin 800 (**2**) shows similar activities \[[@B73-marinedrugs-14-00077]\]. Compared to TGA class 3, TGA class 2 is less active, although batzelladine C (**28**) and L (**38**) and dehydrobatzelladine C (**35**), in general, exhibited a GI~50~ below 1 µg/mL \[[@B73-marinedrugs-14-00077]\]. Finally, crambescidin 816 (**3**) was shown to inhibit cell migration by altering the cytoskeleton dynamics and induced cell death by apoptosis \[[@B75-marinedrugs-14-00077],[@B78-marinedrugs-14-00077]\].

In summary, both TGA class 2 and 3 have been tested against viruses, microbes, and several cancer cell lines. The wide-ranging biological activity of this class of natural products can be in part attributed to the cationic nature of the guanidinium functional group that can participate in a large number of non-covalent molecular interactions \[[@B77-marinedrugs-14-00077]\]. In general, TGA from class 3 exhibited better activities compared to TGA from class 2 \[[@B73-marinedrugs-14-00077]\]. Within TGA class 3, ptilomycalin A (**1**) and crambescidin 800 (**2**) showed similar activities in all assays, suggesting that the hydroxyl group of the right-handed portion in crambescidin 800 (**2**) did not affect the bioactivity. Nevertheless, 16β-hydroxycrambescidin 359 (**16**) did not show any significant antimicrobial activity, suggesting that the hydroxyl group, located on the pentacycle at C-16, diminished the activity \[[@B73-marinedrugs-14-00077]\]. Further studies are needed to confirm this hypothesis. This could be assessed by evaluating the inhibitory activities of crambescidins 816 (**3**), 830 (**4**) and 844 (**5**), as they carry the same hydroxyl moiety as crambescidin 800 (**2**) and another hydroxyl located in the pentacycle at C-13. In parallel, several batzelladines have been reported to disrupt protein--protein interactions. Elucidation of the mechanism by which protein--protein interactions are modulated by these molecules is of great interest, since protein--protein associations are important in all the aspects of cell biochemistry. Moreover, small molecules that influence protein--protein association would be new biological tools and potential therapeutic agents. In particular, batzelladines or their derivatives may prove to be applicable for AIDS treatment. Batzelladines A--E (**26**--**30**) block interaction between the surface of the HIV envelope glycoprotein gp120 and the extracellular domains of human CD4 receptor protein \[[@B66-marinedrugs-14-00077]\]. A subset of batzelladines exhibited also potential immunosuppressive activity as they induce dissociation of the complex between the protein kinase p56^lck^ and CD4 \[[@B67-marinedrugs-14-00077]\]. Synthetic derivatives of batzelladines were reported to disrupt Nef--p53, Nef--actin, and Nef--p56^lck^ interactions \[[@B77-marinedrugs-14-00077]\]. Bewley *et al.* tested a series of 28 synthetic batzelladine-like GA analogues on HIV-1 cell fusion assay, to find structure-activity relationships \[[@B76-marinedrugs-14-00077]\]. According to this study, the greater the rigidity of the molecule, the less biologically active it is. Moreover, they have shown that the most active compounds tested were compounds which contain two tricyclic guanidine moieties connected by an alkyl ester linkage including eight heavy atoms, such as batzelladines F (**31**) and G (**32**). Batzelladines biological properties could be dramatically affected by the ester side chains. For example, batzelladine A (**26**) inhibits the binding of HIV glycoprotein gp120 to CD4 receptors, whereas batzelladine D (**29**) has no known biological activity \[[@B77-marinedrugs-14-00077]\].

Finally, several derivatives that do not feature an ester side chain may still exhibit interesting biological properties such as the antibacterial and antimalarial activities of merobatzelladines A (42) and B (43) \[[@B69-marinedrugs-14-00077]\].

4. Conclusions {#sec4-marinedrugs-14-00077}
==============

Several batzelladine- and crambescidin-like guanidine alkaloids have been isolated from Poecilosclerida marine sponges. Their biosynthesis, or the biosynthesis of their precursors, may involve symbiotic microorganisms \[[@B79-marinedrugs-14-00077]\]. This class of natural products is structurally unique as all the derivatives are constituted by a tricyclic guanidinium ring system, to which are appended different substituents. This significant structural diversity has led to wide-ranging biological properties with mainly antiviral, antimicrobial (including antifungal, antibacterial, anti-yeast, and antiparasitic), and antitumor activities. In addition to the biomimetic strategy, a number of groups completed the total synthesis of several of these alkaloids by developing new synthetic methodologies. Although there are many efficient and stereoselective synthetic routes towards this class of natural products, there is not yet one method that would allow entry into all of the cores of this family. Nonetheless, a number of these syntheses have enabled the establishment of their relative and absolute stereochemical configurations. In conclusion, several of these alkaloids and their synthetic analogs were prepared on a large enough scale to allow further biological testing, including few structure-activity relationship studies. Ongoing studies may provide us with further clues regarding this class of Marine Natural Products.
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![Geographical repartition of new TGA (triazaacenaphthylene guanidine alkaloids) discovered from 1989 to 2015. Graphic ^©^ d-maps.com \[[@B72-marinedrugs-14-00077]\]. Used with permission.](marinedrugs-14-00077-g001){#marinedrugs-14-00077-f001}

![Number of new TGA discovered since 1989. The number of TGA discovered per year (grey bars) and the cumulative data representing the total number of TGA discovered (black curve) are presented from 1989 to 2015.](marinedrugs-14-00077-g002){#marinedrugs-14-00077-f002}
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Related (**A**) C-8 cycloheptanic spiro ring and (**B**) C-8 cyclopentanic spiro ring crambescidin-like GA.
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![Non-related crambescidin-like GA.](marinedrugs-14-00077-g004){#marinedrugs-14-00077-f004}

![Crambescin A (**54**).](marinedrugs-14-00077-g005){#marinedrugs-14-00077-f005}

###### 

Related batzelladine-like GA with different right-handed tricycles.

![](marinedrugs-14-00077-g006a)

![](marinedrugs-14-00077-g006b)

![Unrelated batzelladine-like GA.](marinedrugs-14-00077-g007){#marinedrugs-14-00077-f007}

![(**A**) Crambescin C1 (**55**); (**B**) crambine A (**56**); (**C**) netamine M (**57**); and (**D**) ptilocaulin (**58**).](marinedrugs-14-00077-g008){#marinedrugs-14-00077-f008}

![Current numbering scheme for: (**A**) C-8 cycloheptanic spiro ring crambescidin-like GA; and (**B**) batzelladine-like GA.](marinedrugs-14-00077-g009){#marinedrugs-14-00077-f009}
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(**A**) Ptilomycalin A (**1**) ^1^H-^1^H COSY NMR spectrum in CD~3~OD (personal data); and (**B**) labeled ptilomycalin A (**1**).
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![(**A**) Batzelladine F (**31**) ^1^H-^1^H COSY NMR spectrum in CD~3~OD (adapted from Patil *et al.* \[[@B67-marinedrugs-14-00077]\]); and (**B**) labeled batzelladine F (**31**).](marinedrugs-14-00077-g011){#marinedrugs-14-00077-f011}

marinedrugs-14-00077-t001_Table 1

###### 

Reviewed crambescidin-like GA (guanidine alkaloids) from 1989 to 2015.

  Metabolite                              Species                                       Sampling Site                            Discovery Year   Guanidine Moiety   Biological Activity         Synthesis Described   Ref.
  --------------------------------------- --------------------------------------------- ---------------------------------------- ---------------- ------------------ --------------------------- --------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  ptilomycalin A (**1**)                  *Hemimycale* sp. *Ptilocaulis spiculifer*     Red sea                                  1989             1                  Av, Am, At                  Yes                   \[[@B42-marinedrugs-14-00077],[@B51-marinedrugs-14-00077],[@B73-marinedrugs-14-00077]\]
  crambescidin 800 (**2**)                *Crambe crambe*                               Palma de Mallorca, Mediterranean sea     1991             1                  Av, Am, At                  Yes                   \[[@B54-marinedrugs-14-00077],[@B55-marinedrugs-14-00077],[@B56-marinedrugs-14-00077],[@B73-marinedrugs-14-00077],[@B74-marinedrugs-14-00077]\]
  crambescidin 816 (**3**)                *Crambe crambe*                               Palma de Mallorca, Mediterranean sea     1991             1                  Av, At, Ca^2+^ antagonist   No                    \[[@B52-marinedrugs-14-00077],[@B55-marinedrugs-14-00077],[@B56-marinedrugs-14-00077],[@B75-marinedrugs-14-00077]\]
  crambescidin 830 (**4**)                *Crambe crambe*                               Palma de Mallorca, Mediterranean sea     1991             1                  n.t.                        No                    \[[@B55-marinedrugs-14-00077]\]
  crambescidin 844 (**5**)                *Crambe crambe*                               Palma de Mallorca, Mediterranean sea     1991             1                  Av                          No                    \[[@B55-marinedrugs-14-00077],[@B56-marinedrugs-14-00077]\]
  13,14,15-isocrambescidine 800 (**6**)   *Crambe crambe*                               Banyuls, Mediterranean sea               1993             1                  Not active                  Yes                   \[[@B36-marinedrugs-14-00077],[@B42-marinedrugs-14-00077],[@B56-marinedrugs-14-00077]\]
  crambidine (**7**)                      *Crambe crambe*                               Banyuls, Mediterranean sea               1993             1                  n.t.                        Yes                   \[[@B45-marinedrugs-14-00077],[@B49-marinedrugs-14-00077],[@B52-marinedrugs-14-00077]\]
  neofolitispate 1 (**8**)                *Neofolitispa dianchora*                      Andaman Islands, Indian Ocean            1999             1                  Av                          No                    \[[@B57-marinedrugs-14-00077]\]
  neofolitispate 2 (**9**)                *Neofolitispa dianchora*                      Andaman Islands, Indian Ocean            1999             1                  Av                          Yes                   \[[@B57-marinedrugs-14-00077]\]
  neofolitispate 3 (**10**)               *Neofolitispa dianchora*                      Andaman Islands, Indian Ocean            1999             1                  Av                          No                    \[[@B57-marinedrugs-14-00077]\]
  crambescidin 359 (**11**)               *Monanchora ungiculata*                       Belize, North Atlantic Ocean             2000             1                  n.t.                        Yes                   \[[@B33-marinedrugs-14-00077],[@B41-marinedrugs-14-00077],[@B48-marinedrugs-14-00077],[@B53-marinedrugs-14-00077]\]
  crambescidin 431 (**12**)               *Monanchora ungiculata*                       Belize, North Atlantic Ocean             2000             1                  n.t.                        No                    \[[@B53-marinedrugs-14-00077]\]
  crambescidin 826 (**13**)               *Monanchora* sp.                              Palau, Pacific Ocean                     2003             1                  Av                          No                    \[[@B54-marinedrugs-14-00077]\]
  crambescidin acid (**14**)              *Monanchora ungiculata*                       Maldive Islands, Indian Ocean            2004             1                  At                          No                    \[[@B58-marinedrugs-14-00077]\]
  crambescidic acid (**15**)              *Monanchora unguifera Monanchora dianchora*   Panama, Caribbean side, Atlantic Ocean   2005             1                  n.t.                        No                    \[[@B59-marinedrugs-14-00077]\]
  16β-hydroxycrambescidin 359 (**16**)    *Monanchora unguifera*                        Jamaica, North Atlantic Ocean            2007             1                  Am                          No                    \[[@B73-marinedrugs-14-00077]\]
  ptilomycalin D (**17**)                 *Monanchora dianchora*                        Madagascar, Indian Ocean                 2007             1                  n.t.                        No                    \[[@B60-marinedrugs-14-00077]\]
  monanchocidin A (**18**)                *Monanchora pulchra*                          Urup Island, North Pacific Ocean         2010             1                  At                          No                    \[[@B61-marinedrugs-14-00077]\]
  monanchocidin B (**19**)                *Monanchora pulchra*                          Urup Island, North Pacific Ocean         2011             1                  At                          No                    \[[@B62-marinedrugs-14-00077]\]
  monanchocidin C (**20**)                *Monanchora pulchra*                          Urup Island, North Pacific Ocean         2011             1                  At                          No                    \[[@B62-marinedrugs-14-00077]\]
  monanchocidin D (**21**)                *Monanchora pulchra*                          Urup Island, North Pacific Ocean         2011             1                  At                          No                    \[[@B62-marinedrugs-14-00077]\]
  monanchocidin E (**22**)                *Monanchora pulchra*                          Urup Island, North Pacific Ocean         2011             1                  At                          No                    \[[@B62-marinedrugs-14-00077]\]
  monanchomycalin A (**23**)              *Monanchora pulchra*                          Urup Island, North Pacific Ocean         2012             1                  At                          No                    \[[@B63-marinedrugs-14-00077]\]
  monanchomycalin B (**24**)              *Monanchora pulchra*                          Urup Island, North Pacific Ocean         2012             1                  n.t.                        No                    \[[@B63-marinedrugs-14-00077]\]
  monanchomycalin C (**25**)              *Monanchora pulchra*                          Urup Island, North Pacific Ocean         2013             1                  n.t.                        No                    \[[@B64-marinedrugs-14-00077]\]

Am, antimicrobial activity; Av, antiviral activity; At, antitumoral activity; and n.t., not tested.

marinedrugs-14-00077-t002_Table 2

###### 

Reviewed batzelladine-like GA from 1989 to 2015.

  Metabolites                            Species                  Sampling Site                                Discovery Year   Guanidine Moiety   Biological Activities   Synthesis Described   Ref.
  -------------------------------------- ------------------------ -------------------------------------------- ---------------- ------------------ ----------------------- --------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  batzelladine A (**26**)                *Batzella* sp.           Bahamas, North Atlantic Ocean                1996             3                  Am, Av                  Yes                   \[[@B32-marinedrugs-14-00077],[@B46-marinedrugs-14-00077],[@B66-marinedrugs-14-00077]\]
  batzelladine B (**27**)                *Batzella* sp.           Bahamas, North Atlantic Ocean                1996             3                  Av                      No                    \[[@B66-marinedrugs-14-00077]\]
  batzelladine C (**28**)                *Batzella* sp.           Bahamas, North Atlantic Ocean                1996             2                  Av, Am, At              No                    \[[@B66-marinedrugs-14-00077],[@B73-marinedrugs-14-00077]\]
  batzelladine D (**29**)                *Batzella* sp.           Bahamas, North Atlantic Ocean                1996             2                  Av, Am                  Yes                   \[[@B37-marinedrugs-14-00077],[@B40-marinedrugs-14-00077],[@B46-marinedrugs-14-00077],[@B47-marinedrugs-14-00077],[@B66-marinedrugs-14-00077]\]
  batzelladine E (**30**)                *Batzella* sp.           Bahamas, North Atlantic Ocean                1996             2                  n.t.                    Yes                   \[[@B35-marinedrugs-14-00077],[@B66-marinedrugs-14-00077]\]
  batzelladine F (**31**)                *Batzella* sp.           Jamaica, North Atlantic Ocean                1997             2                  Am                      Yes                   \[[@B30-marinedrugs-14-00077],[@B39-marinedrugs-14-00077],[@B42-marinedrugs-14-00077],[@B67-marinedrugs-14-00077]\]
  batzelladine G (**32**)                *Batzella* sp.           Jamaica, North Atlantic Ocean                1997             2                  Av                      No                    \[[@B67-marinedrugs-14-00077]\]
  batzelladine H (**33**)                *Batzella* sp.           Jamaica, North Atlantic Ocean                1997             2                  Av                      No                    \[[@B67-marinedrugs-14-00077]\]
  batzelladine I (**34**)                *Batzella* sp.           Jamaica, North Atlantic Ocean                1997             2                  Av                      No                    \[[@B67-marinedrugs-14-00077]\]
  dehydrobatzelladine C (**35**)         *Monanchora arbuscula*   Belize, North Atlantic Ocean                 2000             2                  Av, Am, At              Yes                   \[[@B43-marinedrugs-14-00077],[@B53-marinedrugs-14-00077],[@B73-marinedrugs-14-00077]\]
  batzelladine J (**36**)                *Monanchora unguifera*   Panama, North Atlantic Ocean                 2005             3                  n.t.                    No                    \[[@B59-marinedrugs-14-00077]\]
  batzelladine K (**37**)                *Monanchora unguifera*   Jamaica, North Atlantic Ocean                2007             1                  n.t.                    No                    \[[@B73-marinedrugs-14-00077]\]
  batzelladine L (**38**)                *Monanchora unguifera*   Jamaica, North Atlantic Ocean                2007             2                  Av, Am, At              No                    \[[@B73-marinedrugs-14-00077]\]
  batzelladine M (**39**)                *Monanchora unguifera*   Jamaica, North Atlantic Ocean                2007             2                  Av, Am, At              No                    \[[@B73-marinedrugs-14-00077]\]
  batzelladine N (**40**)                *Monanchora unguifera*   Jamaica, North Atlantic Ocean                2007             2                  Av, At                  No                    \[[@B73-marinedrugs-14-00077]\]
  clathriadic acid (**41**)              *Clathria calla*         Martinique, North Atlantic Ocean             2009             1                  Am                      No                    \[[@B68-marinedrugs-14-00077]\]
  merobatzelladine A (**42**)            *Monanchora* sp.         Amami-Oshima Island, North Pacific Ocean     2009             1                  Am                      No                    \[[@B50-marinedrugs-14-00077],[@B69-marinedrugs-14-00077]\]
  merobatzelladine B (**43**)            *Monanchora* sp.         Amami-Oshima Island, North Pacific Ocean     2009             1                  Am                      Yes                   \[[@B69-marinedrugs-14-00077]\]
  norbatzelladine A (**44**)             *Monanchora arbuscula*   Guadeloupe Island, North Atlantic Ocean      2009             3                  Am, At                  No                    \[[@B68-marinedrugs-14-00077]\]
  norbatzelladine L (**45**)             *Clathria calla*         Martinique, North Atlantic Ocean             2009             2                  Am, At                  No                    \[[@B68-marinedrugs-14-00077]\]
  dinorbatzelladine A (**46**)           *Monanchora arbuscula*   Guadeloupe island, North Atlantic Ocean      2009             3                  Am, At                  No                    \[[@B68-marinedrugs-14-00077]\]
  dinorbatzelladine B (**47**)           *Monanchora arbuscula*   Guadeloupe island, North Atlantic Ocean      2009             3                  n.t.                    No                    \[[@B68-marinedrugs-14-00077]\]
  dinordehydrobatzelladine B (**48**)    *Monanchora arbuscula*   Guadeloupe island, North Atlantic Ocean      2009             3                  Am, At                  No                    \[[@B68-marinedrugs-14-00077]\]
  dihomodehydrobatzelladine C (**49**)   *Monanchora arbuscula*   Guadeloupe island, North Atlantic Ocean      2009             2                  Am, At                  No                    \[[@B68-marinedrugs-14-00077]\]
  batzellamide A (**50**)                *Monanchora arbuscula*   Rio de Janeiro state, South Atlantic Ocean   2015             2                  n.t.                    No                    \[[@B70-marinedrugs-14-00077]\]
  hemibatzelladine J (**51**)            *Monanchora arbuscula*   Rio de Janeiro state, South Atlantic Ocean   2015             2                  n.t.                    No                    \[[@B70-marinedrugs-14-00077]\]
  Δ^19^-hemibatzelladine J (**52**)      *Monanchora arbuscula*   Rio de Janeiro state, South Atlantic Ocean   2015             2                  n.t.                    No                    \[[@B70-marinedrugs-14-00077]\]
  Δ^200^-hemibatzelladine J (**53**)     *Monanchora arbuscula*   Rio de Janeiro state, South Atlantic Ocean   2015             2                  n.t.                    No                    \[[@B70-marinedrugs-14-00077]\]

Am, antimicrobial activity; Av, antiviral activity; At, antitumor activity; and n.t., not tested.

marinedrugs-14-00077-t003_Table 3

###### 

GA classes.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No           Class 1                              Class 2                              Class 3                               Class 4                              Ref.
  ------------ ------------------------------------ ------------------------------------ ------------------------------------- ------------------------------------ ---------------------------------
  1            ![](marinedrugs-14-00077-i001.jpg)   ![](marinedrugs-14-00077-i002.jpg)   ![](marinedrugs-14-00077-i002.jpg)\   ![](marinedrugs-14-00077-i003.jpg)   \[[@B70-marinedrugs-14-00077]\]
                                                                                         +1 or more guanidine moiety                                                

  Sponges \*   *Batzella*\                          *Clathria*\                          *Batzella*\                           *Acanthella*\                        \-
               *Crambe*\                            *Crambe*\                            *Monanchora*                          *Arenochalina*\                      
               *Pseudaxinella*\                     *Hemimycale*\                                                              *Batzella*\                          
               (*Ptilocaulis*)                      *Monanchora*\                                                              *Biemna*\                            
                                                    *Neofolitispa*\                                                            *Clathria*\                          
                                                    *Ptilocaulis*                                                              *Monanchora*\                        
                                                                                                                               *Ptilocaulis*                        

  2            ![](marinedrugs-14-00077-i001.jpg)   ![](marinedrugs-14-00077-i002.jpg)   ![](marinedrugs-14-00077-i004.jpg)\   ![](marinedrugs-14-00077-i003.jpg)   \-
                                                                                         *n* = 1 or 3                                                               

  Sponges \*   *Batzella*\                          *Batzella*\                          *Crambe*\                             *Acanthella*\                        \-
               *Crambe*\                            *Clathria*\                          *Hemimycale*\                         *Arenochalina*\                      
               *Pseudaxinella*\                     *Monanchora*                         *Monanchora*\                         *Batzella*\                          
               (*Ptilocaulis*)                                                           *Neofolitispa*\                       *Biemna*\                            
                                                                                         *Ptilocaulis*                         *Clathria*\                          
                                                                                                                               *Monanchora*\                        
                                                                                                                               *Ptilocaulis*                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Sponges without any genus revision made.

marinedrugs-14-00077-t004_Table 4

###### 

Characteristic TGA signals.

  Atom Number                      Crambescidin-Like GA Signals   Batzelladine-Like GA Signals
  -------------------------------- ------------------------------ ------------------------------
  H~a~ \*                          dd from 2.8 to 2.5 ppm         m from 2.8 to 2.5 ppm
  H~b~ \*                          m from 4.6 to 3.9 ppm          m from 4.6 to 3.9 ppm
  H~c~ \*                          dt toward 4.3 ppm              m toward 4.3 ppm
  H~d~ \*                          d from 3.5 to 2.9 ppm          dd from 3.5 to 2.9 ppm
  H~4~ \* et H~5~ \* double bond   2 m toward 5.5 ppm             No signal

\*: for a, b, c, d, 4 and 5 attributions, see above; d, doublet; dd, doublet of doublets; dt, doublet of triplets; m, multiplet.

marinedrugs-14-00077-t005_Table 5

###### 

TGA Mass Spectrometry (MS) data.

  Metabolites                                *m/z* (\[M + H\]^+^ Unless Specified) and Δppm Found         Ref.
  ------------------------------------------ ------------------------------------------------------------ ---------------------------------
  ptilomycalin A (**1**)                     977.7915 (1.0 mmu) for the bis(trifluoroacetyl) derivative   \[[@B51-marinedrugs-14-00077]\]
  crambescidin 800 (**2**)                   801.6205 (1.3 mmu)                                           \[[@B55-marinedrugs-14-00077]\]
  crambescidin 816 (**3**)                   817.6151 (1.6 mmu)                                           \[[@B55-marinedrugs-14-00077]\]
  crambescidin 830 (**4**)                   831.6300 (2.3 mmu)                                           \[[@B55-marinedrugs-14-00077]\]
  crambescidin 844 (**5**)                   845.6471 (0.9 mmu)                                           \[[@B55-marinedrugs-14-00077]\]
  13, 14, 15 -isocrambescidine 800 (**6**)   927.6521 (1.3 mmu) for the acetylated compound               \[[@B52-marinedrugs-14-00077]\]
  crambidine (**7**)                         967.6415 (6.8 mmu) for the acetylated compound               \[[@B52-marinedrugs-14-00077]\]
  neofolitispate 1 (**8**)                   686 (no HRMS data)                                           \[[@B57-marinedrugs-14-00077]\]
  neofolitispate 2 (**9**)                   672 (no HRMS data)                                           \[[@B57-marinedrugs-14-00077]\]
  neofolitispate 3 (**10**)                  658 (no HRMS data)                                           \[[@B57-marinedrugs-14-00077]\]
  crambescidin 359 (**11**)                  359.2567 (0.6 mmu)                                           \[[@B53-marinedrugs-14-00077]\]
  crambescidin 431 (**12**)                  431.2780 (0.4 mmu)                                           \[[@B53-marinedrugs-14-00077]\]
  crambescidin 826 (**13**)                  827.6389 (1.5 mmu)                                           \[[@B54-marinedrugs-14-00077]\]
  crambescidin acid (**14**)                 404.2541 (2.2 mmu)                                           \[[@B58-marinedrugs-14-00077]\]
  crambescidic acid (**15**)                 658.4781 (1.4 mmu)                                           \[[@B59-marinedrugs-14-00077]\]
  16β-hydroxycrambescidin 359 (**16**)       376.2617 (1.7 mmu)                                           \[[@B73-marinedrugs-14-00077]\]
  ptilomycalin D (**17**)                    627.4994 \*                                                  \[[@B60-marinedrugs-14-00077]\]
  monanchocidin (A) (**18**)                 859.6267 (3.0 mmu)                                           \[[@B61-marinedrugs-14-00077]\]
  monanchocidin B (**19**)                   831.5978 (3.4 mmu)                                           \[[@B62-marinedrugs-14-00077]\]
  monanchocidin C (**20**)                   845.6150 (4.0 mmu)                                           \[[@B62-marinedrugs-14-00077]\]
  monanchocidin D (**21**)                   831.5920 (3.4 mmu)                                           \[[@B62-marinedrugs-14-00077]\]
  monanchocidin E (**22**)                   845.6120 (1.0 mmu)                                           \[[@B62-marinedrugs-14-00077]\]
  monanchomycalin A (**23**)                 813.6574 (0.2 mmu)                                           \[[@B63-marinedrugs-14-00077]\]
  monanchomycalin B (**24**)                 785.6259 (0.4 mmu)                                           \[[@B63-marinedrugs-14-00077]\]
  monanchomycalin C (**25**)                 813.6578 (0.3 mmu) and \[M + 2H\]^2+^ 407.3336 (0.7 mmu)     \[[@B64-marinedrugs-14-00077]\]
  batzelladine A (**26**)                    768.5839 (2.4 mmu)                                           \[[@B66-marinedrugs-14-00077]\]
  batzelladine B (**27**)                    738.5356 (3.8 mmu)                                           \[[@B66-marinedrugs-14-00077]\]
  batzelladine C (**28**)                    489.3903 (1.4 mmu)                                           \[[@B66-marinedrugs-14-00077]\]
  batzelladine D (**29**)                    463.3740 \*\*                                                \[[@B66-marinedrugs-14-00077]\]
  batzelladine E (**30**)                    487.3728 (3.2 mmu)                                           \[[@B66-marinedrugs-14-00077]\]
  batzelladine F (**31**)                    624.5096 (0.6 mmu)                                           \[[@B67-marinedrugs-14-00077]\]
  batzelladine G (**32**)                    668,5353 (1.3 mmu)                                           \[[@B67-marinedrugs-14-00077]\]
  batzelladine H (**33**)                    609.4488 (0.4 mmu)                                           \[[@B67-marinedrugs-14-00077]\]
  batzelladine I (**34**)                    \[[@B67-marinedrugs-14-00077]\]                              
  dehydrobatzelladine C (**35**)             487.3711 (4.9 mmu)                                           \[[@B53-marinedrugs-14-00077]\]
  batzelladine J (**36**)                    750.5361 (3.3 mmu)                                           \[[@B59-marinedrugs-14-00077]\]
  batzelladine K (**37**)                    250.2322 (3.9 mmu)                                           \[[@B73-marinedrugs-14-00077]\]
  batzelladine L (**38**)                    653.5458 (2.4 mmu) and \[M + 2H\]^2+^ 327.2798 (1.8 mmu)     \[[@B73-marinedrugs-14-00077]\]
  batzelladine M (**39**)                    \[M + 2H\]^2+^ 298.2399 (1.0 mmu)                            \[[@B73-marinedrugs-14-00077]\]
  batzelladine N (**40**)                    \[M + 2H\]^2+^ 312.2546 (1.0 mmu)                            \[[@B73-marinedrugs-14-00077]\]
  clathriadic acid (**41**)                  318.2173 (1.0 mmu)                                           \[[@B68-marinedrugs-14-00077]\]
  merobatzelladine A (**42**)                360.3444 (6.6 mmu)                                           \[[@B69-marinedrugs-14-00077]\]
  merobatzelladine B (**43**)                306.2909 (7.0 mmu)                                           \[[@B69-marinedrugs-14-00077]\]
  norbatzelladine A (**44**)                 754.5705 (0.7 mmu)                                           \[[@B68-marinedrugs-14-00077]\]
  norbatzelladine L (**45**)                 639.5327 (0.3 mmu)                                           \[[@B68-marinedrugs-14-00077]\]
  dinorbatzelladine A (**46**)               740.5547 (0.9 mmu)                                           \[[@B68-marinedrugs-14-00077]\]
  dinorbatzelladine B (**47**)               710.5074 (1.2 mmu)                                           \[[@B68-marinedrugs-14-00077]\]
  dinordehydrobatzelladine B (**48**)        708.4919 (1.0 mmu)                                           \[[@B68-marinedrugs-14-00077]\]
  dihomodehydrobatzelladine C (**49**)       515.4064 (1.3 mmu)                                           \[[@B68-marinedrugs-14-00077]\]
  batzellamide A (**50**)                    541.3878 (1.2 mmu)                                           \[[@B70-marinedrugs-14-00077]\]
  hemibatzelladine J (**51**)                449.3238 (0.2 mmu)                                           \[[@B70-marinedrugs-14-00077]\]
  Δ^19^-hemibatzelladine J (**52**)          447.3092 (0.8 mmu)                                           \[[@B70-marinedrugs-14-00077]\]
  Δ^200^-hemibatzelladine J (**53**)         \[[@B70-marinedrugs-14-00077]\]                              

\* Calculated *m/z* value: 626.4975; reported *m/z* value: 627.4994; \*\* not specified.

marinedrugs-14-00077-t006_Table 6

###### 

Characteristic MS^2^ TGA signals.

  *m/z* Fragment      *m/z* Fragment Loss   Fragment                                                Ref.
  ------------------- --------------------- ------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  358 (or 359)                              Crambescidin core                                       \[[@B53-marinedrugs-14-00077],[@B54-marinedrugs-14-00077],[@B55-marinedrugs-14-00077],[@B59-marinedrugs-14-00077]\]
  322 or 336 or 350                         Batzelladine core + *n* = 6, 7 or 8 carbon side chain   \[[@B53-marinedrugs-14-00077],[@B66-marinedrugs-14-00077],[@B67-marinedrugs-14-00077],[@B68-marinedrugs-14-00077],[@B73-marinedrugs-14-00077]\]
  114                 113                   ![](marinedrugs-14-00077-i005.jpg)                      \[[@B53-marinedrugs-14-00077],[@B59-marinedrugs-14-00077],[@B66-marinedrugs-14-00077]\]
                      101                   ![](marinedrugs-14-00077-i006.jpg)                      \[[@B61-marinedrugs-14-00077],[@B62-marinedrugs-14-00077]\]
  Intense 18          17                    Carboxylic acid                                         \-
  Intense 48          47                                                                            

marinedrugs-14-00077-t007_Table 7

###### 

TGA antiviral activities.

  EC~50~ (µM Unless Specified)           HIV-1   HSV-1   HBV    Ref.                          
  -------------------------------------- ------- ------- ------ ------------------ ---------- -----------------------------------------------------------------------------------------
  ptilomycalin A (**1**)                 0.011   n.t.    n.t.   0.25 \*            n.t.       \[[@B51-marinedrugs-14-00077]\]
  crambescidin 800 (**2**)               0.04    1--3    n.t.   1.25 µg/well ^a^   n.t.       \[[@B54-marinedrugs-14-00077],[@B55-marinedrugs-14-00077],[@B73-marinedrugs-14-00077]\]
  crambescidin 816 (**3**)               n.t.    n.t.    n.t.   1.25 µg/well ^a^   n.t.       \[[@B55-marinedrugs-14-00077]\]
  crambescidin 844 (**5**)               n.t.    n.t.    n.t.   1.25 µg/well ^a^   n.t.       \[[@B55-marinedrugs-14-00077]\]
  13,14,15-isocrambescidin 800 (**6**)   n.t.    n.t.    n.t.   NA                 n.t.       \[[@B56-marinedrugs-14-00077]\]
  neofolitispate 1 (**8**)               n.t.    n.t.    n.t.   n.t.               7.4 \*\*   \[[@B57-marinedrugs-14-00077]\]
  neofolitispate 2 (**9**)               n.t.    n.t.    n.t.   n.t.                          
  neofolitispate 3 (**10**)              n.t.    n.t.    n.t.   n.t.                          
  crambescidin 826 (**13**)              n.t.    1--3    n.t.   n.t.               n.t.       \[[@B54-marinedrugs-14-00077]\]
  batzelladine A (**26**)                n.t.    n.t.    29     n.t.               n.t.       \[[@B66-marinedrugs-14-00077]\]
  batzelladine B (**27**)                n.t.    n.t.    31     n.t.               n.t.       \[[@B66-marinedrugs-14-00077]\]
  batzelladine C (**28**)                7.7     n.t.    n.t.   n.t.               n.t.       \[[@B73-marinedrugs-14-00077]\]
  batzelladine D (**29**)                n.t.    n.t.    72     n.t.               n.t.       \[[@B66-marinedrugs-14-00077]\]
  dehydrobatzelladine C (**35**)         5.5     n.t.    n.t.   n.t.               n.t.       \[[@B73-marinedrugs-14-00077]\]
  batzelladine L (**38**)                1.6     n.t.    n.t.   n.t.               n.t.       \[[@B73-marinedrugs-14-00077]\]
  batzelladine M (**39**)                7.7     n.t.    n.t.   n.t.               n.t.       \[[@B73-marinedrugs-14-00077]\]
  batzelladine N (**40**)                2.4     n.t.    n.t.   n.t.               n.t.       \[[@B73-marinedrugs-14-00077]\]

HIV, Human immunodeficiency virus; PBMC, Peripheral Blood Mononuclear cells; gp, glycoprotein; HSV, *Herpes simplex* virus; HBV, Human hepatitis B virus; n.t., not tested, NA, not active; \* converted from µM to µg/mL; \*\* calculated from compound (**9**) molecular weight; ^a^ Diffuse cytotoxicity at 1.25 µg/well.

marinedrugs-14-00077-t008_Table 8

###### 

TGA antimicrobial activities.

  IC~50~ (Values are Expressed in µg/mL Unless Specified)   Bacteria   Yeast   Fungi   Parasites   Ref.                                                                                                                                            
  --------------------------------------------------------- ---------- ------- ------- ----------- ------ ------ ------ ------ ------ ------- ------ --------- -------- --------------------------------- --------------------------------- ------ -------------------------------------------------------------
  ptilomycalin A (**1**)                                    0.25       0.30    1.0     \>128       10     n.t.   0.15   0.10   1.25   0.12    0.11   0.08 \*   n.t.     5.9                               n.t.                              n.t.   \[[@B68-marinedrugs-14-00077],[@B73-marinedrugs-14-00077]\]
  crambescidin 800 (**2**)                                  0.20       0.35    0.95    46.5        15     n.t.   0.15   0.10   1.25   0.11    0.13   n.t.      n.t.     6.80                              n.t.                              n.t.   \[[@B73-marinedrugs-14-00077]\]
  16β-hydroxycrambescidin 800 (**16**)                      NA         NA      NA      \>128       NA     n.t.   NA     NA     NA     3.8     NA     NA        n.t.     n.t.                              n.t.                              n.t.   \[[@B73-marinedrugs-14-00077]\]
  batzelladine A (**26**)                                   n.t.       n.t.    n.t.    n.t.        n.t.   n.t.   n.t.   n.t.   n.t.   n.t.    n.t.   0.2\*     n.t.     n.t.                              n.t.                              n.t.   \[[@B68-marinedrugs-14-00077]\]
  batzelladine C (**28)**                                   0.20       0.30    10      34.7        0.9    n.t.   0.90   0.40   5.0    0.09    0.11   n.t.      n.t.     5.5                               n.t.                              n.t.   \[[@B73-marinedrugs-14-00077]\]
  batzelladine D (**29**)                                   n.t.       n.t.    n.t.    n.t.        n.t.   n.t.   n.t.   n.t.   n.t.   n.t.    n.t.   n.t.      0.9 \*   n.t.                              29 \*                             n.t.   \[[@B70-marinedrugs-14-00077]\]
  batzelladine F (**31**)                                   n.t.       n.t.    n.t.    n.t.        n.t.   n.t.   n.t.   n.t.   n.t.   n.t.    n.t.   n.t.      2.5 \*   n.t.                              3.1 \*                            n.t.   \[[@B70-marinedrugs-14-00077]\]
  dehydrobatzelladine C (**35**)                            0.40       0.70    NA.     37.7        1.0    n.t.   1.0    0.6    20     0.073   0.13   n.t.      n.t.     5.70                              n.t.                              n.t.   \[[@B73-marinedrugs-14-00077]\]
  batzelladine L (**38**)                                   0.35       0.40    3.50    1.68        0.25   n.t.   0.40   0.55   2.5    0.073   0.10   0.2 \*    1.3 \*   1.90                              1.3 \*                            n.t.   \[[@B68-marinedrugs-14-00077],[@B73-marinedrugs-14-00077]\]
  batzelladine M (**39**)                                   3.0        5.0     NA      28.5        3.50   n.t.   6.0    8.0    NA     0.21    0.27   n.t.      n.t.     8.50                              n.t.                              n.t.   \[[@B73-marinedrugs-14-00077]\]
  batzelladine N (**40**)                                   n.t.       n.t.    n.t.    3.18        n.t.   n.t.   n.t.   n.t.   n.t.   n.t.    n.t.   n.t.      n.t.     n.t.                              n.t.                              n.t.   \[[@B73-marinedrugs-14-00077]\]
  clathriadic acid (**41**)                                 n.t.       n.t.    n.t.    n.t.        n.t.   n.t.   n.t.   n.t.   n.t.   n.t.    n.t.   1.4 \*    n.t.     n.t.                              n.t.                              n.t.   \[[@B68-marinedrugs-14-00077]\]
  merobatzelladine A (**42**)                               n.t.       n.t.    n.t.    n.t.        n.t.   a      n.t.   n.t.   n.t.   0.48    n.t.   n.t.      n.t.     0.24                              \[[@B69-marinedrugs-14-00077]\]          
  merobatzelladine B (**43**)                               n.t.       n.t.    n.t.    n.t.        n.t.   n.t.   n.t.   n.t.   0.97   n.t.    n.t.   n.t.      0.24     \[[@B69-marinedrugs-14-00077]\]                                            
  norbatzelladine A (**44**)                                n.t.       n.t.    n.t.    n.t.        n.t.   n.t.   n.t.   n.t.   n.t.   n.t.    n.t.   0.2 \*    n.t.     n.t.                              n.t.                              n.t.   \[[@B68-marinedrugs-14-00077]\]
  norbatzelladine L (**45**)                                n.t.       n.t.    n.t.    n.t.        n.t.   n.t.   n.t.   n.t.   n.t.   n.t.    n.t.   0.3 \*    1.3 \*   n.t.                              4.4 \*                            n.t.   \[[@B68-marinedrugs-14-00077],[@B70-marinedrugs-14-00077]\]
  dinorbatzelladine A (**46**)                              n.t.       n.t.    n.t.    n.t.        n.t.   n.t.   n.t.   n.t.   n.t.   n.t.    n.t.   1.7 \*    n.t.     n.t.                              n.t.                              n.t.   \[[@B68-marinedrugs-14-00077]\]
  dinordehydrobatzelladine B (**48**)                       n.t.       n.t.    n.t.    n.t.        n.t.   n.t.   n.t.   n.t.   n.t.   n.t.    n.t.   0.6 \*    n.t.     n.t.                              n.t.                              n.t.   \[[@B68-marinedrugs-14-00077]\]
  dihomodehydrobatzelladine C (**49**)                      n.t.       n.t.    n.t.    n.t.        n.t.   n.t.   n.t.   n.t.   n.t.   n.t.    n.t.   2.3 \*    n.t.     n.t.                              n.t.                              n.t.   \[[@B68-marinedrugs-14-00077]\]

*S. aureus*, *Staphyloccocus aureus*; MRSA, Methicilline resistant *Staphyloccocus aureus*; *P. aeruginosa*, *Pseudomonas aeruginosa*; *M. tuberculosis*, *Mycobacterium tuberculosis*; *M. intracellulare*, *Mycobacterium intracellulare*; *V. angillarum*, *Vibrio angillarum*; *C. albicans*, *Candida albicans*; *A. fumigatus*, *Aspergillus fumigatus*; *P. falciparum*, *Plasmodium falciparum*; *L. infatum*, *Leishmania infatum*; *L. donovani*, *Leishmania donovani*; *T. cruzi*, *Trypanosoma cruzi*; *T. brucei brucei*, *Trypanosoma brucei brucei*; AC, active concentration; NA, not active according to the authors; n.t., not tested; \* converted from µM to µg/mL; a, 9--10 mm/50 µg.

marinedrugs-14-00077-t009_Table 9

###### 

TGA antitumor activities (values are expressed in µg/mL unless specified).

                                                   Prostate   Ovary   Breast   Melanoma   Lung   Leukemia   Pancreas   Colon            Cervix          Ref.                                                                 
  --------------------------------------- -------- ---------- ------- -------- ---------- ------ ---------- ---------- ---------------- --------------- ------- ------ ------------- --------------- ------ ---------------- ---------------------------------
  ptilomycalin A (**1**)                  GI~50~   0.05       0.04    0.07     n.t.       0.03   0.08       0.04       n.t.             n.t.            0.04    0.03   n.t.          0.05            0.05   0.04             \[[@B73-marinedrugs-14-00077]\]
  TGI                                     1.22     1.74       0.54    n.t.     0.11       1.23   1.33       n.t.       n.t.             0.99            0.19    n.t.   2.14          2.04            0.22                    
  LC~50~                                  5.21     n.t.       n.t.    n.t.     0.98       9.79   9.72       n.t.       n.t.             0.98            5.37    n.t.   9.79          8.48            3.21                    
  crambescidin 800 (**2**)                GI~50~   0.19       0.05    0.16     n.t.       0.04   0.11       0.02       n.t.             n.t.            0.04    0.04   n.t.          0.08            0.08   0.05             \[[@B73-marinedrugs-14-00077]\]
  TGI                                     1.38     2.50       0.56    n.t.     0.11       1.36   0.06       n.t.       n.t.             1.53            0.23    n.t.   2.29          2.02            0.21                    
  LC~50~                                  7.01     n.t.       n.t.    n.t.     1.70       9.68   6.73       n.t.       n.t.             8.66            5.75    n.t.   8.97          8.50            1.58                    
  crambescidin 816 (**3**)                GI~50~   n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   IC~50~ 0.24   n.t.            n.t.   n.t.             \[[@B52-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  LC~50~                                  n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  monanchocidin A (**18**)                GI~50~   n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             IC~50~ 4.4 \*   n.t.    n.t.   n.t.          n.t.            n.t.   IC~50~ 10.1 \*   \[[@B61-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.                                                  
  LC~50~                                  n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.                                                  
  monanchocidin B (**19**)                GI~50~   n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       IC~50~ 0.17 \*   n.t.            n.t.    n.t.   n.t.          n.t.            n.t.   n.t.             \[[@B62-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  LC~50~                                  n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  monanchocidin C (**20**)                GI~50~   n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       IC~50~ 0.09 \*   n.t.            n.t.    n.t.   n.t.          n.t.            n.t.   n.t.             \[[@B62-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  LC~50~                                  n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  monanchocidin D (**21**)                GI~50~   n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       IC~50~ 0.69 \*   n.t.            n.t.    n.t.   n.t.          n.t.            n.t.   n.t.             \[[@B62-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  LC~50~                                  n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  monanchocidin E (**22**)                GI~50~   n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       IC~50~ 0.55 \*   n.t.            n.t.    n.t.   n.t.          n.t.            n.t.   n.t.             \[[@B62-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  LC~50~                                  n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  monanchomycalin A (**23**)              GI~50~   n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       IC~50~ 0.10 \*   n.t.            n.t.    n.t.   n.t.          n.t.            n.t.   n.t.             \[[@B63-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  LC~50~                                  n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  monanchomycalin B (**24**)              GI~50~   n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       IC~50~ 0.11 \*   n.t.            n.t.    n.t.   n.t.          n.t.            n.t.   n.t.             \[[@B63-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  LC~50~                                  n.t.     n.t.       n.t.    n.t.     n.t.       n.t.   n.t.       n.t.       n.t.             n.t.            n.t.    n.t.   n.t.          n.t.                                    
  batzelladine C (**28**)                 GI~50~   0.68       0.81    0.66     n.t.       1.45   1.40       0.62       n.t.             n.t.            0.55    0.65   n.t.          2.06            2.25   0.70             \[[@B73-marinedrugs-14-00077]\]
  TGI                                     2.27     3.43       2.89    n.t.     3.67       3.42   3.01       n.t.       n.t.             2.03            2.16    n.t.   4.37          4.72            2.22                    
  LC~50~                                  0.69     n.t.       n.t.    n.t.     9.24       8.31   n.t.       n.t.       n.t.             7.14            6.70    n.t.   9.29          0.99            6.50                    
  dehydrobatzelladine C (**35**)          GI~50~   0.46       0.73    0.23     n.t.       0.89   1.19       0.48       n.t.             n.t.            0.43    0.48   n.t.          1.60            2.07   0.48             \[[@B73-marinedrugs-14-00077]\]
  TGI                                     1.91     4.17       1.14    n.t.     3.48       3.24   2.42       n.t.       n.t.             1.83            1.77    n.t.   3.68          4.48            1.52                    
  LC~50~                                  7.15     n.t.       n.t.    n.t.     n.t.       8.81   n.t.       n.t.       n.t.             8.66            7.50    n.t.   8.47          9.69            5.45                    
  batzelladine L (**38**)                 GI~50~   0.44       0.52    0.23     n.t.       0.88   1.30       n.t.       n.t.             n.t.            0.34    4.96   n.t.          1.09            n.t.   0.38             \[[@B73-marinedrugs-14-00077]\]
  TGI                                     1.39     1.74       0.56    n.t.     2.18       9.99   n.t.       n.t.       n.t.             1.33            n.t.    n.t.   2.41          n.t.            1.16                    
  LC~50~                                  3.78     5.01       2.10    n.t.     4.95       n.t.   n.t.       n.t.       n.t.             4.38            n.t.    n.t.   5.36          n.t.            3.58                    
  batzelladine M (**39**)                 GI~50~   1.77       2.28    1.12     n.t.       1.18   3.80       n.t.       n.t.             n.t.            1.22    3.56   n.t.          1.99            n.t.   1.64             \[[@B73-marinedrugs-14-00077]\]
  TGI                                     3.44     5.08       2.51    n.t.     4.66       n.t.   0.00       n.t.       n.t.             3.58            n.t.    n.t.   3.56          n.t.            3.05                    
  LC~50~                                  6.66     n.t.       5.59    n.t.     n.t.       n.t.   0.00       n.t.       n.t.             n.t.            n.t.    n.t.   6.37          n.t.            5.68                    
  batzelladine N (**40**)                 GI~50~   1.39       1.78    1.12     n.t.       1.47   1.94       0.66       n.t.             n.t.            1.37    1.31   n.t.          1.96            4.42   0.59             \[[@B73-marinedrugs-14-00077]\]
  TGI                                     3.12     4.97       3.84    n.t.     3.41       4.29   3.27       n.t.       n.t.             3.50            3.11    n.t.   4.16          n.t.            1.80                    
  LC~50~                                  7.04     n.t.       n.t.    n.t.     7.97       9.47   n.t.       n.t.       n.t.             8.97            7.35    n.t.   8.85          n.t.            5.13                    
  clathriadic acid (**41**)               GI~50~   n.t.       n.t.    n.t.     13.5       n.t.   \>30       n.t.       n.t.             n.t.            n.t.    \>30   n.t.          n.t.            n.t.   n.t.             \[[@B68-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    \>30     n.t.       \>30   n.t.       n.t.       n.t.             n.t.            \>30    n.t.   n.t.          n.t.            n.t.                    
  LC~50~                                  n.t.     n.t.       n.t.    \>30     n.t.       \>30   n.t.       n.t.       n.t.             n.t.            \>30    n.t.   n.t.          n.t.            n.t.                    
  norbatzelladine A (**44**)              GI~50~   n.t.       n.t.    n.t.     3.8        n.t.   2.1        n.t.       n.t.             n.t.            n.t.    1.6    n.t.          TC~50~ 4.7 µM   n.t.   n.t.             \[[@B68-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    6.4      n.t.       4.6    n.t.       n.t.       n.t.             n.t.            3.2     n.t.   n.t.          n.t.                                    
  LC~50~                                  n.t.     n.t.       n.t.    11.4     n.t.       8.6    n.t.       n.t.       n.t.             n.t.            5.7     n.t.   n.t.          n.t.                                    
  norbatzelladine L (**45**)              GI~50~   n.t.       n.t.    n.t.     0.7        n.t.   1.1        n.t.       n.t.             n.t.            n.t.    1.9    n.t.          n.t.            n.t.   n.t.             \[[@B68-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    1.9      n.t.       2.1    n.t.       n.t.       n.t.             n.t.            4.2     n.t.   n.t.          n.t.            n.t.                    
  LC~50~                                  n.t.     n.t.       n.t.    4.8      n.t.       4.2    n.t.       n.t.       n.t.             n.t.            7.6     n.t.   n.t.          n.t.            n.t.                    
  dinorbatzelladine A (**46**)            GI~50~   n.t.       n.t.    n.t.     3.0        n.t.   1.9        n.t.       n.t.             n.t.            n.t.    1.9    n.t.          n.t.            n.t.   n.t.             \[[@B68-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    3.8      n.t.       4.2    n.t.       n.t.       n.t.             n.t.            4.2     n.t.   n.t.          n.t.            n.t.                    
  LC~50~                                  n.t.     n.t.       n.t.    5.4      n.t.       7.6    n.t.       n.t.       n.t.             n.t.            7.6     n.t.   n.t.          n.t.            n.t.                    
  dinordehydro-batzelladine B (**48**)    GI~50~   n.t.       n.t.    n.t.     n.t.       n.t.   7.9        n.t.       n.t.             n.t.            n.t.    6.2    n.t.          n.t.            n.t.   n.t.             \[[@B68-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    n.t.     n.t.       \>14   n.t.       n.t.       n.t.             n.t.            \> 14   n.t.   n.t.          n.t.            n.t.                    
  LC~50~                                  n.t.     n.t.       n.t.    n.t.     n.t.       \>14   n.t.       n.t.       n.t.             n.t.            \> 14   n.t.   n.t.          n.t.            n.t.                    
  dihomodehydro-batzelladine C (**49**)   GI~50~   n.t.       n.t.    n.t.     6.1        n.t.   \>30       n.t.       n.t.             n.t.            n.t.    \>30   n.t.          n.t.            n.t.   n.t.             \[[@B68-marinedrugs-14-00077]\]
  TGI                                     n.t.     n.t.       n.t.    9.8      n.t.       \>30   n.t.       n.t.       n.t.             n.t.            \>30    n.t.   n.t.          n.t.            n.t.                    
  LC~50~                                  n.t.     n.t.       n.t.    15.6     n.t.       \>30   n.t.       n.t.       n.t.             n.t.            \>30    n.t.   n.t.          n.t.            n.t.                    

n.t., not tested; \* calculated value from µM to µg/mL.
